Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | ACACA | Q13085 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24302650 | 0.90 | RORC (0.43) | PARP10PARP15FFAR4SLC6A2SLC6A4 | |
| SCHEMBL20207072 | 0.88 | PARP10 (0.48) | PARP10PARP15FFAR4FFAR1 | |
| SCHEMBL21736840 | 0.88 | PARP10 (0.48) | PARP10PARP15SLC6A2SLC6A4HTR3A | |
| SCHEMBL24302656 | 0.87 | SCN1A (0.46) | PARP10PARP15SLC6A2SLC6A4HTR3A | |
| SCHEMBL18374246 | 0.85 | ACACB (0.43) | PARP10PARP15FFAR4ACACBACACA | |
| SCHEMBL20201713 | 0.80 | ACACB (0.40) | PARP10PARP15FFAR4SLC6A2SLC6A4 | |
| SCHEMBL14901056 | 0.80 | PARP10 (0.55) | PARP10PARP15FFAR4SLC6A2SLC6A4 | |
| SCHEMBL17658890 | 0.80 | NQO1 (0.48) | FFAR4FFAR1 | |
| SCHEMBL21350592 | 0.79 | CA1 (0.47) | PARP10PARP15FFAR4ACACBACACA | |
| SCHEMBL22390599 | 0.79 | PARP10 (0.43) | PARP10PARP15FFAR4FFAR1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4105216-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-12-21 | — | — | EP | disclosed |
| US-10570100-B2 | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-02-25 | — | — | US | disclosed |
| WO-2018128720-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | WO | disclosed |
| US-20180194740-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194740-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | DUT, DPYD, TYMP | PARP10 683/4885PARP15 569/4885FFAR4 4296/4885 |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | PARP10 509/4885PARP15 645/4885FFAR4 731/4885 |
| US-10570100-B2 | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage | DUT, DPYD, TYMP | PARP10 683/4885PARP15 569/4885FFAR4 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.